素在功能性便秘中与体征性症状障碍 - 从倾向性得分匹配的队列研究中的有效性和安全性
Bin Yang1, Xiangying Feng1, Qinxian Huang2
1Digestive Surgery, Xijing Hospital of Digestive Diseases. Fourth Military Medical University.
西有效地治疗功能性便秘 (FC) 与并发性体征性症状障碍 (SSD). 这种治疗在六个月内改善了肠道功能和心理症状,证明了这一点.
科学领域:
- 胃肠病学 胃肠病学
- 精神病学是一个精神病学.
- 临床治疗学 临床治疗学
背景情况:
- 功能性便秘 (FC) 经常与体质症状障碍 (SSD) 发生,特别是在具有挑战性的病例中.
- 在这些患者中,便秘症状可能更多地源于强烈的身体体验,而不是主要的肠道功能障碍.
研究的目的:
- 评估弗洛克塞丁在伴并发性SSD患者治疗FC的疗效和安全性.
主要方法:
- 一项队列研究涉及316名患有体征症状的FC患者.
- 161名患者接受了素,155人接受了聚乙烯糖醇 (PEG).
- 倾向性得分匹配为比较分析创建了77对对.
主要成果:
- 六个月后,40.26%的素组实现了主要终点 (≥3次完全自发性肠道排便/周),而PEG组的22.08% (P=0.009).
- 素显著改善了次要结果:CSBM频率,肠道症状严重程度,GAD-9分数和患者满意度.
- 较高的基线GAD-9分数 (>9) 预测了治疗有效性 (OR=5.01;P<0.01).
结论:
- 在SSD的FC患者中,Fluoxetine在六个月内证明了安全性和有效性.
- 这种药物通过改善便秘和相关的心理症状来提供双重好处.
更多相关视频
03:50Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
